Seminars in Cancer Biology

Papers
(The H4-Index of Seminars in Cancer Biology is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Editorial Board671
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]472
Small secretory proteins of immune cells can modulate gynecological cancers426
Advances in biology and novel treatments of SCLC390
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications386
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation332
Multifaceted role of chemokines in solid tumors: From biology to therapy290
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects260
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation255
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator246
Emerging applications of bacteria as antitumor agents239
Critical DNA damaging pathways in tumorigenesis238
Deregulated transcription factors in the emerging cancer hallmarks236
Editorial Board228
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features226
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis215
Gut microbes in gastrointestinal cancers210
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]193
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]192
Immune cellular components and signaling pathways in the tumor microenvironment191
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer187
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives183
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy170
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy166
Origins and molecular effects of hypoxia in cancer164
Innovative trial design in precision oncology163
The IL-1 family in tumorigenesis and antitumor immunity162
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions162
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies161
Anticancer properties of chimeric HDAC and kinase inhibitors159
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers159
The emerging role of metabolic interventions in uveal melanoma158
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?155
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives152
Atrial fibrillation in cancer patients: Epidemiology, identification and management145
The role of deiodinases on metabolic alteration in cancer141
Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction139
Editorial Board130
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools130
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma129
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine129
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging129
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]127
Reprogramming of glycolysis by chemical carcinogens during tumor development126
Editorial Board126
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways122
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers120
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective118
Anticancer natural products targeting immune checkpoint protein network117
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis112
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy108
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems106
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics105
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine103
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer102
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics101
How far have we explored fungi to fight cancer?98
Editorial Board98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer98
Editorial Board98
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer92
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?92
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment92
Editorial Board92
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy92
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells92
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer91
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles91
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer91
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape89
Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives88
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders88
Microbiota and lung cancer87
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling83
The microbiome-immune cell interaction network: Advancing tumor immunotherapy83
Clinical utility of whole-genome sequencing in precision oncology83
Microorganisms in cancer tertiary lymphoid structure formation82
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer81
Analytical demands to use whole-genome sequencing in precision oncology81
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications81
Advancements in small cell lung cancer80
Metabolic reprogramming of tumor microenviroment by engineered bacteria80
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy80
0.1497209072113